Ovarian Reserve
Cross-source consensus on Ovarian Reserve from 1 sources and 5 claims.
1 sources · 5 claims
Benefits
Risks & contraindications
Other
Other
Other
Highlighted claims
- AMH is used as a biomarker of ovarian reserve. — ATOPE study protocol: a randomised controlled trial comparing cystectomy and plasma vapourisation in endometriomas under 6 cm, with an observational arm for sclerotherapy in larger cysts
- Postoperative AMH is included as a secondary ovarian reserve outcome. — ATOPE study protocol: a randomised controlled trial comparing cystectomy and plasma vapourisation in endometriomas under 6 cm, with an observational arm for sclerotherapy in larger cysts
- Cystectomy causes a measurable postoperative decline in AMH. — ATOPE study protocol: a randomised controlled trial comparing cystectomy and plasma vapourisation in endometriomas under 6 cm, with an observational arm for sclerotherapy in larger cysts
- Preoperative AMH is collected within 12 months before surgery at baseline. — ATOPE study protocol: a randomised controlled trial comparing cystectomy and plasma vapourisation in endometriomas under 6 cm, with an observational arm for sclerotherapy in larger cysts
- AFC preservation was significantly better after plasma vapourisation than after cystectomy in a retrospective study of 30 women. — ATOPE study protocol: a randomised controlled trial comparing cystectomy and plasma vapourisation in endometriomas under 6 cm, with an observational arm for sclerotherapy in larger cysts